A Phase 2 , Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Using Premedication With OsrhCT and Dimethicone Emulsion During Upper Gastrointestinal Endoscopy Examination.

Study was designed to evaluate efficacy of OsrhCT and Dimethicone emulsion before upper endoscopy on visibility of gastric mucosa.
A total of 336 subjects (both male and female) are expected to be enrolled in this trial.

Start Date19 Dec 2024

Sponsor / Collaborator

Wuhan Healthgen Biotechnology Corp.

[+1]

NCT06713421

/ RecruitingNot ApplicableIIT

The Effects of Premedication With Pronase and Postural Exercise on Mucosal Cleanliness During Painless Esophagogastroduodenoscopy: A Prospective, Multicenter, Randomized Controlled Study Based on Artificial Intelligence Assessment

Gastric cancer and esophageal cancer are common malignant tumors that threaten people's life and health. Esophagogastroduodenoscopy (EGD) is an important tool for screening upper gastrointestinal tumors, especially early tumors, and an effective method for detecting other upper gastrointestinal lesions, including ulcers and polyps. However, during EGD examination, mucus and foam can reduce the cleanliness of the mucosa and limit the operator's visual field, resulting in missed lesions and misdiagnosis. Previous studies have shown that preoperative medication with pronase and dimeticone is correlated with the improvement of upper gastrointestinal mucosal cleanliness. However, the number of samples in such studies is limited, and the artificial judgment is not objective enough to evaluate the cleanliness of upper digestive tract mucosa. And, whether a postural exercise is necessary for premedication with pronase or dimeticone remains unclear. Our team design this experiment to examine the efficacy of using premedication of dimeticone/pronase with a postural exercise on visualization of the mucosa before painless EGD. The investigators aim to provide new evidence to optimize the use of premedication with EGD.

Start Date01 Dec 2024

Sponsor / Collaborator

Changhai Hospital of Shanghai

[+25]

IRCT20090808002306N9

/ RecruitingPhase 4IIT

The clinical efficacy of a dermal formulation of Dimethicone in the treatment of plantar dermatitis in children aged two to six years

Start Date10 Mar 2024

Sponsor / Collaborator

Isfahan University of Medical Sciences

100 Clinical Results associated with Dimethicone

100 Translational Medicine associated with Dimethicone

100 Patents (Medical) associated with Dimethicone

220

Literatures (Medical) associated with Dimethicone

25 Feb 2025·HONG KONG MEDICAL JOURNAL

Use of pronase in screening for early cancers of the upper gastrointestinal tract

Article

Author: Lu, Linzhi ; Liu, Jindian ; Li, Shihua ; Wu, Zhengqi ; Zhao, Guangyuan ; Wang, Guiqi ; Zhang, Zhiyi ; Qin, Tianyan

INTRODUCTION:

This study aimed to investigate the effectiveness of pronase in improving the detection rate of early cancer and enhancing visual field clarity during gastroscopy in China.

METHODS:

In total, 1450 patients who participated in an early diagnosis and treatment programme of upper gastrointestinal cancer in Wuwei, Gansu Province between 2020 and 2021 were enrolled. Cluster randomisation was utilised at the community level. All patients underwent endoscopy and biopsy. The experimental group (n=725) received pronase granules and dimethicone prior to gastroscopy; the control group (n=725) received dimethicone alone. Endoscopic visibility scores, examination durations, and lesion detection rates were recorded for both groups.

RESULTS:

Visibility scores for all regions of the stomach were significantly lower in the experimental group than in the control group (P<0.001). This finding remained consistent after adjustment for confounding factors in multiple linear regression analysis. The detection rate of precancerous lesions and early cancer was significantly higher in the experimental group than in the control group (77.5% vs 62.5%; P<0.001). Binary logistic regression analysis indicated that the likelihood of detecting early cancer was greater in the experimental group, with an odds ratio of 3.840 (95% confidence interval=1.204-12.241; P=0.023). Also, average gastroscopy time was significantly shorter in the experimental group than in the control group (6.52±2.51 min vs 10.03±1.23 min, t=33.81; P=0.001).

CONCLUSION:

The administration of pronase prior to gastroscopy enhances visual field clarity, reduces examination time, and increases the detection rates of precancerous lesions and early cancer.

01 Nov 2024·Journal of Wound Ostomy and Continence Nursing

Characteristics of Diaper Dermatitis in Patients Aged 0-24 Months After Congenital Heart Disease and the Effects of a Diaper Dermatitis Care Bundle

Article

Author: Huang, Li-Chi ; Chin, Pei-Ju ; Liao, Li-Na

PURPOSE:

The purpose of this study was to examine characteristics of diaper dermatitis (DD) in critically ill patients aged 0 to 24 months following surgery for congenital heart disease (CHD), the effects of a diaper dermatitis care bundle (DDCB), and factors associated with the development of DD in this population.

DESIGN:

Nonrandomized comparison cohort study with a historical comparison group.

SUBJECTS AND SETTING:

Convenience sampling was used to identify children aged 0 to 24 months undergoing CHD and cared for in a pediatric intensive care unit in central Taiwan (Taichung). The sample comprised 54 participants; 24 were in the historical comparison group and 30 received the DDCB.

METHODS:

The rate of DD from the historical comparison group was compared to that in an intervention group managed with a bundle of interventions used to prevent and manage DD, which includes the routine use of a topical skin protectant. The participants in the historical comparison group received usual care to prevent and manage DD including routine cleansing with a moistened, disposable cloth every 3 hours and following defecation or urination. The DDCB comprised diaper changes at least every 3 hours and as needed after soiling, along with the routine application of a dimethicone and sodium hyaluronate-based skin protectant before diaper changes. Both groups were evaluated for use of an antifungal cream when candidiasis was present.

RESULTS:

Participants managed with the DDCB have a significantly lower rate of DD than the historical comparison group who received routine care (41.65% vs 6.67%, P = .002). Univariate logistic regression showed an odds ratio of 0.10 (95% confidence interval of 0.019-0.520, P = .006), suggesting that the DDCB acted as a protective factor against the development of DD. Multivariate analysis of the historical comparison group indicated that non-cyanotic heart disease was associated with a lower likelihood of postoperative DD compared to those with cyanotic heart disease (odds ratio = 0.01, 95% confidence interval of 0.000-0.946, P = .047).

CONCLUSIONS:

Managing critically ill patients with a DDCB recovering from cardiac surgery significantly decreased the incidence of DD. We recommend routine use of this type of care bundle for preventing DD in this vulnerable population in all children with CHD, with particular attention being paid to this with cyanotic CHD.

01 Nov 2024·JPGN reports

Kinetic sand! A tale of sandy times

Article

Author: Haricharan, Ramanathapura ; Ahuja, Kaweeta ; Ahuja, Kanya ; Muhammad, Umer ; Patel, Pratikkumar

Abstract:

Kinetic magnetic sand, composed of ultra‐fine sand and dimethicone in a 98%–2% ratio, is a versatile sensory toy known for its moldable properties and structural stability (1). Despite the name, it lacks actual magnetic features. Ingesting kinetic sand can pose risks, including choking and gastrointestinal issues, especially in young children. This case report details a unique incident involving a 3‐year‐old who ingested a significant amount of kinetic sand. Although the sand's ingredients are generally hypoallergenic and nontoxic, its grainy texture presented challenges for retrieval. The patient was closely monitored, and ultimately, the sand passed without complications. While no official guidelines exist for managing such cases, individual assessments, considering factors such as ingestion time, symptoms, and age, are crucial for determining the appropriate course of action, which may range from observation to more invasive procedures like endoscopy or surgery.

News (Medical) associated with Dimethicone

03 May 2023

·www.biospace.com

Resilia Pharmaceuticals Announces Return to Market of Neosalus® Cream and Neosalus® Lotion

Neosalus® Products Are Second Relaunch Announced by Resilia in Less Than One Month ATLANTA, May 3, 2023 /PRNewswire/ -- Resilia Pharmaceuticals, Inc. announced today that it has brought Neosalus® Cream and Neosalus® Lotion back to the market. Neosalus® Lotion is a non-steroidal anti-inflammatory prescription product that offers topical treatment for the management of skin disorders, including atopic dermatitis and allergic contact dermatitis. These products had not been available due to supply chain disruptions that occurred as a result of the COVID-19 public health crisis. Resilia Pharmaceuticals Brings Neosalus® Cream and Neosalus® Lotion Back to Market; Follows April 2023 Solace Relaunch Resilia acquired the rights to make, market and sell the Neosalus® products in December 2020. Neosalus® Cream received regulatory clearance from the US FDA in April 2009. Neosalus® Lotion was launched in November 2011. Both Neosalus® Lotion and Neosalus® Cream, use patented Proderm Technology® to help provide skin barrier repair, protection, and hydration1. In addition, the Neosalus® line of products is specially formulated with several key ingredients that can promote healthy skin: dimethicone to help restore the skin barrier and reduce trans-epidermal water loss (TEWL)1,2; glycerin, a humectant to help retain moisture1; and stearic/palmitic acids to produce ceramides, cholesterol, and other free fatty acids in the ratio the skin needs1. All Neosalus® products are non-comedogenic and petrolatum-free and do not contain steroids or alcohol1,3. "We could not be more pleased to restore the supply and bring Neosalus® Cream and Neosalus® Lotion back to patients and prescribers," said Harsha Murthy, Executive Chairman of the Board of Resilia Pharmaceuticals. "Patients and prescribers have been contacting us over the last two years asking when they will be able to get these products. These products will now be available nationwide in pharmacies, clinics and dermatologists' offices where patients, in consultation with their health care providers, can get the relief they need." Murthy continued, "We at Resilia are especially proud that, along with our relaunch of Solace® Eczema Cream that we announced on April 19th of this year, we are demonstrating how to create value for patients and investors by keeping high-quality, reasonably priced therapeutics on the market." Andrew Shales, Chief Executive Officer of Resilia, said "Dermatitis has many causes and appears in several forms. Multiple Neosalus® dosage forms offer convenient options to meet patients' site-specific needs – Neosalus® Cream is often used to treat problem dry skin on the hands, face, and elbows and Neosalus® Lotion is often used for total body coverage, including the face. Patients may particularly like the steroid-free characteristics of Neosalus®1,3. This is something we heard often from prescribers and past patients." Mike Leone, Chief Operating Officer of Resilia, said "In addition to the therapeutic benefits of Neosalus® Cream and Neosalus® Lotion, patients will likely appreciate the cosmetic elegance of Proderm Technology®. Unlike some creams and lotions which tend to leave the skin feeling greasy after application, Neosalus®, a water-lipid based formulation, absorbs quickly, spreads easily, and is non-greasy1. Patients can resume their work and daily activities immediately after applying Neosalus®, thus enhancing compliance and maximizing treatment results. We have shipped Neosalus® so that prescription drug wholesalers can make the products available to their pharmacy, clinic and physician customers." About Resilia Pharmaceuticals™. Resilia Pharmaceuticals, Inc™. is a portfolio company of Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products (www. peakpharmapartners.com). Headquartered in Atlanta, Georgia, Resilia Pharmaceuticals' prescription product line consists of Recedo® topical gel, the #1 prescribed Rx scar treatment over the past 5 years3; Ecoza® (econazole nitrate) topical foam, 1%; the Neosalus® line, including cream, foam, and lotion formulations for eczema/atopic dermatitis; and Neocera®, a version of Neosalus formulated with ceramides. Santefirm Consumer Healthcare, Inc.™, also headquartered in Atlanta, Georgia, is the Resilia affiliate that sells non-prescription, over-the-counter products. Santefirm currently markets and sells Solace® anti-eczema cream on Amazon. All of Resilia and Santefirm's respective products are marketed and manufactured in the US. To learn more about Resilia Pharmaceuticals, please go to . Citations: Ghadially R, Silvander M. Penetration study results using Proderm Technology foam. Poster presented at: 7th Annual Caribbean Dermatology Symposium; January 15-19, 2008; St Thomas, US Virgin Islands. Zhai H, Brachman F, Pelosi A, et al. A bioengineering study on the efficacy of a skin protectant lotion in preventing SLS-induced dermatitis. Skin Res Technol. 2000:6(2):77-80. Data on file; Atlanta, Georgia. Resilia Pharmaceuticals. 2023 Contact: info@resiliapharmaceuticals.com Phone: 888-998-0770

Drug Approval

13 Apr 2023

·www.medicalplasticsnews.com

DuPont introduces developments in low-cyclic silicone blends

DuPont has announced the introduction of new low-cyclosiloxane silicone elastomer blends and silicone resin blends in response to growing consumer demand for products that address a range of troubling skin conditions. These new topical excipient blends also address the market’s need to comply with evolving REACH regulatory compliance demands and to support the shared commitment of DuPont and its customers to the United Nations Sustainable Development Goals (UN SDGs), particularly UNSDG No. 3 – Good Health and Well Being – which calls for protecting human health and well-being for all people at all ages. “Over-the-counter topical and medical products to address scars, actinic keratosis, atopic dermatitis, psoriasis and other skin conditions are proliferating to meet consumer desires to feel good at every age without compromising skin protection and drug delivery efficiency,” said DuPont Liveo Healthcare Solutions EMEA regional marketing leader Michele Vigliotti. “Meanwhile, regulations on consumer healthcare products continue to evolve to ensure safety and minimise public risk.” In response, DuPont Liveo has developed four new low-cyclosiloxane silicone topical excipient blends. These products are designed to help customers meet the substance of very high concern (SVHC) threshold for concerned cyclosiloxanes – below 0.1% – proposed by REACH regulation (EC) No. 1907/2006. The new DuPont Liveo silicone elastomer blends are: Liveo TE-9320 Silicone Elastomer Blend – a blend of silicone elastomer network swollen in a Dimethicone volatile carrier (ref. INCI names Dimethicone and Dimethicone Crosspolymer) – is a non-occlusive rheology modifier with a skin feel that is characterised by smoothness with a light, silky, non-greasy feel. It contains less than 0.1% D4, D5 and D6. Liveo TE-9330 Silicone Elastomer Blend – a blend of silicone elastomer network swollen in a Dimethicone non-volatile carrier (ref. INCI names Dimethicone and Dimethicone Crosspolymer) – is a non-occlusive thickening agent for anhydrous and water-in-oil emulsions. It delivers a smooth, silky feel and contains less than 0.1% D4, D5 and D6. Potential uses for silicone elastomer blends include topical drug delivery formulations for prescription and over-the-counter products that may improve patient compliance due to their unique sensory feel, including creams for conditions such as atopic dermatitis, psoriasis, and scar and pain management, as well as creams and gels that offer a mattifying effect for acne applications. Silicone elastomer blend technologies also are known for their effectiveness in support of drug release or drug permeation in topical semi-solid formulations thereby providing options to formulators. The new DuPont Liveo silicone resin blends are: Liveo TE-9720 Resin Blend – a blend of silicone resin solubilised in a 100 cSt Dimethicone non-volatile carrier (ref. INCI names Dimethicone and Trimethylsiloxysilicate) – exhibits film-forming behaviour and delivers a long-lasting film that is resistant to water wash-off. In development: Liveo TE-9721 Resin Blend – a blend of silicone resin solubilised in a Caprylyl Methicone volatile carrier (ref. INCI names Caprylyl Methicone and Trimethylsiloxysilicate) – exhibits film-forming behaviour and delivers a long-lasting film that is resistant to water wash-off. Additionally, it offers good compatibility with a wide range of formulation ingredients. Liveo silicone resin blends can be incorporated easily into many product forms, including creams for skin barrier applications, sprays that offer ease of application and protect the skin, and gels for novel product forms in challenging skin conditions. Target indications include skin barriers and protective films for ostomy care; liquid bandages, skin barriers and scar management for wound care; UV protection and sunscreens for skin care; and drug delivery therapy for acne, actinic keratosis, antifungal and pain management in dermal care. “DuPont serves a broad spectrum of consumer and medical topical healthcare applications, from over-the-counter to prescription,” Vigliotti said. “Whether customers are looking for technological expertise, regulatory support, or a broad selection of high-quality topical excipients that are easy to process and patient-friendly, we are here to support them.” Liveo topical silicone excipients include silicone-based materials that allow formulators to develop solutions for the efficient delivery of active pharmaceutical ingredients (APIs) in topical forms like creams, lotions, gels, ointments, sprays or sticks. The excipients support unique and aesthetically appealing formulations, making pharmaceutical finished dosage forms easier to apply and more pleasant to use – without compromising drug delivery efficiency – thereby helping to increase patient compliance. Liveo distributor partner Quimica San Diego is showcasing DuPont’s new developments in low-cyclosiloxanes silicone elastomer blends and silicone resin blends at ExpoFarma 2023 19-21 April from 2 to 9pm at booth 1216 at the World Trade Center in Mexico City, Mexico.

26 Jan 2021

·www.globenewswire.com

How to Prevent and Treat Dry, Chapped Lips; American Academy of Dermatology

ROSEMONT, Ill., Jan. 26, 2021 (GLOBE NEWSWIRE) -- For many people, winter skin probably conjures up images of dry, cracked hands, flaky skin, and windburn. However, the lips can be affected too. And while it may seem that dry, cracked lips are something you have to live with until spring, dermatologists from the American Academy of Dermatology say it’s possible to have soft, supple lips year-round by following a few simple steps. “Cold, dry weather; sun damage; and frequently licking your lips are just some of the reasons your lips might feel dry and chapped this winter,” says board-certified dermatologist Noëlle Sherber, MD, FAAD. “Understanding these causes and anything else that might trigger your chapped lips goes a long way in preventing and treating them.” To prevent and treat dry, chapped lips at home, Dr. Sherber recommends the following tips: Choose non-irritating lip products. Look for lip balms, lipsticks and other lip products that contain ingredients like castor seed oil, ceramides, dimethicone or mineral oil. Make sure your lip product is also labeled “fragrance free” and “hypoallergenic.” Avoid ingredients such as camphor, menthol or eucalyptus, as these can irritate your lips. If your lips burn, sting or tingle after using a lip product, stop using that product. Apply lip balm throughout the day and before you go to bed. If your lips are very dry and cracked, try a thick ointment, such as petroleum jelly. Ointment seals in moisture longer than waxes or oils. Protect your lips outdoors. Apply a lip balm with an SPF of 30 or higher before going outdoors, even in the winter. Look for a lip balm with titanium dioxide and/or zinc oxide and reapply it every two hours while outdoors. Keep your skin hydrated. Drink plenty of water and use a humidifier at home — especially in your bedroom while you sleep. Stop licking, biting or picking at your lips. When your lips feel dry, it may feel natural to wet them by licking them, but this can worsen the problem. When you catch yourself licking your lips, apply a non-irritating lip balm instead. Avoid holding metal items with your lips. Everyday items like paperclips, jewelry and reusable metal straws can irritate your lips. “Chapped lips are usually harmless, however sometimes they can be a sign of a medical condition,” says Dr. Sherber. “If your dry, chapped lips do not heal after following these tips for two to three weeks, talk to a board-certified dermatologist.” These tips are demonstrated in “How to Prevent and Treat Dry, Chapped Lips,” a video posted to the AAD website and YouTube channel. This video is part of the AAD’s “Video of the Month” series, which offers tips people can use to properly care for their skin, hair and nails. To find a board-certified dermatologist in your area, visit aad.org/findaderm. Contact Nicole Dobkin, (847) 240-1746, ndobkin@aad.org Julie Landmesser, (847) 240-1714, JLandmesser@aad.org More Information 7 Dermatologists’ Tips for Healing Dry, Chapped Lips Dry Skin Relief Dry Skin Relief from COVID-19 Handwashing About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 20,000 physicians worldwide, the AAD is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow the AAD on Facebook (American Academy of Dermatology), Twitter (@AADskin), Instagram (@AADskin1), or YouTube (AcademyofDermatology). Editor’s note: The AAD does not promote or endorse any products or services. This content is intended as editorial content and should not be embedded with any paid, sponsored or advertorial content as it could be perceived as an AAD endorsement. To view this release in a media-rich format, go to:

100 Deals associated with Dimethicone

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dimethicone	A03AX13	DB11074

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gastrointestinal Diseases	Japan	Kissei Pharmaceutical Co., Ltd.	01 Aug 1962
Pharmaceutical aids	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02213055 (CTgov)	Phase 2	-	97	LICEMD (LiceMD)	tonzwwoitj = atjjvpilok ndeffklznn (muslfnkmtp, thxxaviejh - vddktntqcn) View more	-	29 Jul 2016
				lindane+malathion+permethrin (Standard Head Lice Product)	iuisflmkgv(jvqmbrbcbh) = vsopofofgn xrttxzhuyo (xnzhtoirbq, nstmjlsjls - yldtjlclol) View more
NCT01992172 (CTgov)	Not Applicable	Dermatitis, Atopic	7	Photocil for Atopic Dermatitis (Photocil for Atopic Dermatitis)	hdiqyyxelz(mmvbhihmik) = yxczmpubfi hfodvedmyf (ptemxjrghm, 2.9) View more	-	25 Mar 2016
				Placebo - Sunscreen (SPF 2) (Placebo - Sunscreen (SPF 2))	rokpqlijkn(cmjcaxcxnq) = hayvejfngp ufzbdkorwt (iaadslgmpi, ljrwfmxrtp - khubljxpum) View more
NCT01992185 (CTgov)	Not Applicable	Vitiligo	15	Photocil for Vitiligo (Photocil for Vitiligo)	neyybjsvki(pyvdoysele) = urkipyzoah enoropkeid (tatuavpzym, 16.8) View more	-	10 Mar 2016
				Placebo - Sunscreen (SPF 2) (Placebo - Sunscreen (SPF 2))	neyybjsvki(pyvdoysele) = ghafszffrm enoropkeid (tatuavpzym, 7.1) View more
NCT01916629 (CTgov)	Not Applicable	Psoriasis vulgaris	12	Photocil for Psoriasis (Photocil for Psoriasis)	riideoeoyf(uhbfzoruyf) = ujsztgpmuz zxidzcikmv (axpqbjdocv, 23.7) View more	-	10 Mar 2016
				Placebo - Sunscreen (SPF 2) (Placebo - Sunscreen (SPF 2))	riideoeoyf(uhbfzoruyf) = kdktlyarwx zxidzcikmv (axpqbjdocv, 8.3) View more
NCT02213055 (Pubmed)	Phase 2	First line	58	100% dimethicone gel	pcobcbluwy(lesigjntmy) = There was one adverse event of skin irritation lasting 10 min ggywtqgtsu (rpxehvvwnr )	-	20 Jun 2015
ISRCTN10431107 (Pubmed \| BMC Public Health)	Phase 3	Pediculus capitis infestation	-	Dimeticone 4% lotion	vyoacufewc(hoflcphapa) = zmynofzzxg inqbtdmosf (izrjfzmjzj ) View more	-	01 Dec 2009
				Dimeticone 4% lotion with nerolidol 2% added	vyoacufewc(hoflcphapa) = hbuzwfogys inqbtdmosf (izrjfzmjzj ) View more
ISRCTN15117709 (Pubmed \| BMC Infect Dis)	Not Applicable	Phthiriasis \| Pediculus capitis infestation \| Lice Infestations	145	Dimeticone	bwnayvydjm(cybrgiecod) = Two mild product-related incidents occurred in the dimeticone group rqxhqahjcz (xophuxxfwr ) View more	Positive	10 Sep 2008
				Permethrin

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dimethicone

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation